IP Library Granted Patent US 10,364,294
Granted Patent B2
US 10,364,294 · App. 15/677,846 · Granted Jul 30, 2019

Methods of preparation of conjugates

Inventors: Nathan Elliott Fishkin (Weymouth, MA); Michael Louis Miller (Framingham, MA); Wei Li (Acton, MA); Rajeeva Singh (Framingham, MA)
Assignee: IMMUNOGEN, INC.
C07K16/30A61K31/5517A61K45/06A61K47/545A61K47/6803A61K47/6849A61K47/6851A61K47/6867C07D487/04C07D519/00A61K2039/505C07K2317/24C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,364,294
App. No.
15/677,846
Granted
Jul 30, 2019
Kind
B2
Abstract

The present invention is directed to methods of preparing a conjugate of a cell-binding agent and a drug (such as a cytotoxic compound). The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents.

Claims (9)

1. A method for preparing a conjugate represented by the following formula:

or a pharmaceutically acceptable salt thereof, the method comprising:

a) reacting a modified cytotoxic compound with a bifunctional crosslinking agent to form a second modified cytotoxic compound, wherein the modified cytotoxic compound is represented by the following formula:

or a pharmaceutically acceptable salt thereof; the bifunctional crosslinking agent is N-succinimidyl-4-(2-pyridyldithio)2-sulfo butanoate (sulfo-SPDB); and the second modified cytotoxic compound is represented by the following formula:

or a pharmaceutically acceptable salt thereof; and,

b) reacting the second modified cytotoxic compound with the antibody at a pH of 4 to 9, to form the conjugate, wherein the second modified cytotoxic compound is not purified before reacting with the antibody in step b) and wherein the antibody is huMY9-6, r is an integer from 1 to 10, Y is —SO 3 M, and M is H, Na + or K + .

2. The method of claim 1 , wherein the modified cytotoxic compound is produced by reacting an imine-containing compound represented by the following formula:

or a pharmaceutically acceptable salt thereof, with an imine reactive reagent, wherein the imine reactive reagent is NaHSO 3 or KHSO 3 .

3. The method of claim 2 , wherein the method further comprising purifying the modified cytotoxic compound prior to step a).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2017
From: FISHKIN, NATHAN ELLIOTT; MILLER, MICHAEL LOUIS; LI, WEI; SINGH, RAJEEVA
To: IMMUNOGEN, INC.
Reel/Frame 043571/0252 →
Continuity (6)
Continuation 15097979 · Apr 13, 2016
Continuation 13397205 · Feb 15, 2012
Provisional Application 61443092 · Feb 15, 2011
Provisional Application 61443062 · Feb 15, 2011
Provisional Application 61483499 · May 6, 2011
Related Publication 20180037659A1 · Feb 8, 2018